$同源康医药-B(0_老虎社区_美港股上老虎

$同源康医药-B(02410)$ 公司下一代KRAS G12C抑制剂TY-9592，预计2026年第三季度可以获批进入临床

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":575877769000312,"tweetId":"575877769000312","gmtCreate":1781609040598,"gmtModify":1781609158744,"author":{"id":4203843771083212,"idStr":"4203843771083212","authorId":4203843771083212,"authorIdStr":"4203843771083212","name":"乐山大佛笑哈哈","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 公司下一代KRAS G12C抑制剂TY-9592，预计2026年第三季度可以获批进入临床</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 公司下一代KRAS G12C抑制剂TY-9592，预计2026年第三季度可以获批进入临床</p></body></html>","text":"$同源康医药-B(02410)$ 公司下一代KRAS G12C抑制剂TY-9592，预计2026年第三季度可以获批进入临床","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/575877769000312","repostId":0,"isVote":1,"tweetType":1,"viewCount":93,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02410"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":87,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}